Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
This 12th biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials in the field of hemato-oncology, covering the publication period from September 1, 2009, through June 30, 2010. Implication for clinical practice and methodological aspects are the main principles used to select trials for this report. Studies on tyrosine kinase inhibitors for patients with chronic myeloid leukemia were identified through electronic search of MEDLINE with a broad search filter that covered all topics in hemato-oncology combined with a highly sensitive search filter for randomized studies as described in the Cochrane Handbook for Systematic Reviews of Interventions.
Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. nicole.skoetz@uk-koeln.de
Nicole
N
Skoetz
Sabine
S
Kluge
Ina
I
Monsef
Kathrin
K
Bauer
Hendrik
H
Siebert
Karl-Anton
KA
Kreuzer
Andreas
A
Engert
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000617:Aminoglycosides / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D003520:Cyclophosphamide / Q000008:administration & dosage; D000069439:Dasatinib; D004164:Diphosphonates / Q000008:administration & dosage; D018572:Disease-Free Survival; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage; D019317:Evidence-Based Medicine; D000079982:Gemtuzumab; D006086:Graft vs Host Disease / Q000188:drug therapy; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
D000305:Adrenal Cortex Hormones; D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001549:Benzamides; D004164:Diphosphonates; D016898:Interferon-alpha; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011994:Recombinant Proteins; D013844:Thiazoles; D004921:Erythropoietin; D000069283:Rituximab; D000068817:Epoetin Alfa; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; D000079982:Gemtuzumab; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D014740:Vidarabine; C024352:fludarabine; D000069439:Dasatinib; D008727:Methotrexate